163 related articles for article (PubMed ID: 8348073)
41. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
Di Raimondo F; LaPushin R; Hersh EM
Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
[TBL] [Abstract][Full Text] [Related]
42. Modulation by interferon alpha of the decreased natural killer activity in patients with glioblastoma.
Lapeña P; Isasi C; Vaquero J; Martinez R; Alvarez-Mon M
Acta Neurochir (Wien); 1991; 109(3-4):109-13. PubMed ID: 1858528
[TBL] [Abstract][Full Text] [Related]
43. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells.
Frey JR; Kamber M; Peck R
Lymphokine Res; 1987; 6(3):215-27. PubMed ID: 3114569
[TBL] [Abstract][Full Text] [Related]
44. Alpha-interferon activates the natural killer system in patients with hairy cell leukemia.
Semenzato G; Pizzolo G; Agostini C; Ambrosetti A; Zambello R; Trentin L; Luca M; Masciarelli M; Chilosi M; Vinante F
Blood; 1986 Jul; 68(1):293-6. PubMed ID: 3719101
[TBL] [Abstract][Full Text] [Related]
45. Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment.
Lauria F; Rondelli D; Raspadori D; Zinzani PL; Benfenati D; Pileri S; Sabattini E; Tura S
Leuk Lymphoma; 1992 May; 7(1-2):103-7. PubMed ID: 1472920
[TBL] [Abstract][Full Text] [Related]
46. Is there a direct differentiation-inducing effect of human recombinant interferon on hairy cell leukemia in vitro?
Gressler VH; Weinkauff RE; Franklin WA; Golomb HM
Cancer; 1989 Jul; 64(2):374-8. PubMed ID: 2500232
[TBL] [Abstract][Full Text] [Related]
47. [Therapy of hairy cell leukemia with interferon].
Brünig K; Fülle HH; Dahmen E; Hellriegel KP
Onkologie; 1988 Aug; 11(4):159-65. PubMed ID: 3054667
[TBL] [Abstract][Full Text] [Related]
48. Long-term killing of natural killer-resistant target cells by interferon-alpha-, interferon-gamma-, and interleukin-2-activated natural killer cells.
Sarzotti M; Klimpel GR; Baron S
Nat Immun Cell Growth Regul; 1989; 8(2):66-75. PubMed ID: 2503715
[TBL] [Abstract][Full Text] [Related]
49. Effect of alpha-IFN on cytokine-induced antigen expression and secretion of TNF, LT and IgM in HCL.
Hassan IB; Lantz M; Sundström C
Leuk Res; 1991; 15(10):903-10. PubMed ID: 1921451
[TBL] [Abstract][Full Text] [Related]
50. Hairy cell leukaemia: observations on natural killer activity in different clinical stages of the disease.
Demeter J; Pálóczi K; Lehoczky D; Benczúr M
Br J Haematol; 1989 Feb; 71(2):239-44. PubMed ID: 2923810
[TBL] [Abstract][Full Text] [Related]
51. The clinical evaluation of hairy cell leukemia.
Demeter J; Porzsolt F
Blood; 1992 Apr; 79(8):2171-3. PubMed ID: 1510754
[No Abstract] [Full Text] [Related]
52. Ultrastructural, immunologic and clinical follow-up of five patients with HCL treated with interferon (IFN) for more than three years.
Mantovani G; Astara G; Curreli L; Lai P; Turnu E; Locci F; Lantini MS; Cossu M; Riva A; Del Giacco GS
Haematologica; 1992; 77(4):326-35. PubMed ID: 1427443
[TBL] [Abstract][Full Text] [Related]
53. Treatment of hairy-cell leukaemia with alpha-interferon (alpha-IFN).
Lauria F; Foà R; Raspadori D; Zinzani PL; Buzzi M; Fierro MT; Bonferroni M; Fanin R; Gallizia C; Michieli MG
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):195-200. PubMed ID: 3356206
[TBL] [Abstract][Full Text] [Related]
54. The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases.
Mandelli F; Cafolla A; Annino L; Amadori S; Gentile A; Bianco P; Dianzani F
J Biol Regul Homeost Agents; 1987; 1(4):177-82. PubMed ID: 3332545
[TBL] [Abstract][Full Text] [Related]
55. Phenotypic and functional characterization of the circulating NK compartment in hairy cell leukaemia.
Foa R; Lauria F; Lusso P; Raspadori D; Fierro MT; Tazzari PL; Caudana L; Matera L
Clin Exp Immunol; 1986 May; 64(2):392-8. PubMed ID: 3742880
[TBL] [Abstract][Full Text] [Related]
56. Hairy-cells are not lysed by NK-cells.
Sigaux F; Chapuis F; Castaigne S; Degos L; Flandrin G; Gluckman JC
Blut; 1987 May; 54(5):319-20. PubMed ID: 3567370
[No Abstract] [Full Text] [Related]
57. Immunosuppressive effects of recombinant interferon-alpha during long-term treatment of cancer patients.
Teichmann JV; Sieber G; Ludwig WD; Ruehl H
Cancer; 1989 May; 63(10):1990-3. PubMed ID: 2702571
[TBL] [Abstract][Full Text] [Related]
58. Increase of NK cell-mediated cytotoxicity of hairy cell leukemia patients after splenectomy.
Bigda J; Myśliwska J; Baran V; Zoltowska A; Hellmann A
Eur J Haematol; 1989 Jul; 43(1):78-9. PubMed ID: 2767244
[No Abstract] [Full Text] [Related]
59. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
[TBL] [Abstract][Full Text] [Related]
60. Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group.
Rai KR
Leuk Lymphoma; 1994; 14 Suppl 1():107-8. PubMed ID: 7820040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
